CION Ameerpet
Immunotherapy Cost & Access
Immunotherapy Through a Clinical Trial — The Free Access Route, Honestly Explained
When the drug is the reason treatment is out of reach, a clinical trial is the one route that can remove that line from the bill entirely — because the sponsor supplies the investigational drug. It is a real route, and for many Indian families the only realistic one. It is also narrow, unpredictable and never assured. This page sets out what is actually free, what still comes out of your pocket, and how to look for a study, with regulatory references to CDSCO and the CTRI register maintained by ICMR.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- The drug can be free — the treatment is not — Sponsors typically supply the investigational drug and the protocol-only tests. Day care, routine monitoring, travel and stay usually stay with you.
- Eligibility is narrow, and it is checked on paper — Cancer type, stage, biomarker report, prior treatment lines and organ function all have to sit inside the protocol. Screening rules many people out.
- You may not receive the study drug — Randomisation can place you on the current standard treatment instead. Read the design in the consent document before you plan a budget around it.
- Information, not recruitment — Nothing here is an offer of a place on a study, and no benefit is promised. We help you check whether a trial is clinically sensible and what it would cost.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The direct answer
Is Immunotherapy Free If You Join a Clinical Trial?
Often the drug is; the whole treatment rarely is. In most cancer drug trials the sponsor supplies the investigational immunotherapy at no charge, plus the extra tests and scans the protocol demands. Day-care administration, routine care, travel and stay usually stay on your bill. Indicative, as of August 2026.
For a large number of Indian families this is not an academic point. The drug is the single largest line on an immunotherapy bill, and when it is removed the arithmetic changes completely. That is why this page is written as a cost page rather than a research page — but the honest version of it has to include what the trial route does not pay for, because that is where families are caught out after cycle one.
| Line on the bill | Buying the treatment yourself | On a clinical trial |
|---|---|---|
| The investigational drug itself | The largest single line, paid cycle after cycle | Supplied by the sponsor at no charge in most drug trials — confirm it in the consent document, not from a webpage |
| Protocol-only tests, scans and biomarker work | Not applicable | Normally paid by the sponsor, because the study is asking for them |
| Screening tests before you are accepted | Not applicable | Usually paid by the study, including where screening ends in your not being eligible |
| Day-care administration — chair time, nursing, IV set, observation | Yours | Usually still yours, unless the protocol states otherwise |
| Routine pre-cycle bloods and standard monitoring | Yours | Usually still yours — this is care you would have needed anyway |
| Response-assessment imaging | Yours. PET-CT is coordinated at partner imaging centres and billed by them | Covered only where the protocol schedules that scan; anything additional remains yours |
| Treating a side effect | Yours | Free medical management is required for an injury related to the trial; an unrelated illness is still yours |
| Travel, stay, attendant time, lost income | Yours | Yours, and often higher — the trial site may not be your nearest centre |
| Continuing treatment after the study ends | You decide, and you buy | Depends entirely on the protocol. Post-trial supply is not automatic |
Everything above is indicative, as of August 2026, and describes how trials commonly work rather than how your trial works. Protocols differ, sponsors differ, and terms change. Nothing on this page confirms that any study will pay for anything in your case — only the signed consent document and the study team’s written answer do that. This page deliberately attaches no price to any named drug or brand.
Did you know?
A genuine trial in India is a public record you can look up. Prospective registration in the Clinical Trials Registry – India (CTRI), run by ICMR’s National Institute of Medical Statistics, is required before the first participant is enrolled, and a trial of a new drug also needs permission from CDSCO and clearance from a registered ethics committee. So an “immunotherapy trial” that appears nowhere in that register, and cannot show you an ethics-committee clearance, is a reason to stop and ask questions rather than to pay money.
What is covered
What Does the Sponsor Actually Cover?
The sponsor pays for what the study asks of you. That means the investigational drug, the protocol-only tests and scans, and the screening visit. It does not usually mean the care you would have needed anyway. The split is written into the consent document and it differs between studies.
Usually paid by the sponsor
- The investigational drug — and, in a randomised study, whatever the comparator arm receives if the study supplies it.
- Protocol-only tests — the extra bloods, ECGs, biomarker or tissue tests that exist only because the study wants the data.
- Protocol-scheduled imaging — scans done on the study’s calendar rather than on ordinary clinical judgement.
- Screening — the tests that decide whether you are eligible, usually including those of people who turn out not to be.
- Medical management of a trial-related injury — required of the sponsor under the New Drugs and Clinical Trials Rules, 2019, which also provide for compensation where an injury or death is found to be related to the trial.
Usually still yours
- Day-care administration — immunotherapy is given as a day-care infusion, and the chair, nursing and observation time are billed as normal.
- Standard monitoring — the pre-cycle counts, liver, kidney and thyroid checks you would have had on treatment anyway.
- Anything unrelated to the trial — an infection, a co-morbidity, an admission for a reason outside the protocol.
- Travel, stay and attendant costs — the largest hidden line on the trial route, because trial sites cluster in a few cities.
- Treatment after the study — if the study ends, closes early, or you come off it, continued supply is a separate question with a separate answer.
Ask for this split in writing before you consent, itemised, with a date on it. A verbal “everything is free” is not something a family can budget against, and it is almost never accurate. Costs, reimbursement rules and protocol terms quoted here are indicative, as of August 2026.
Eligibility
Who Can Actually Join an Immunotherapy Trial?
Fewer patients than hope for it. A protocol defines the cancer type, stage, biomarker profile, number of prior treatments and organ-function thresholds it will accept, and those lines are not negotiable. Screening rules out many patients who otherwise look suitable. Enrolment is never assured, even after screening begins.
- Exact cancer type and stage — not the broad category. A study may accept one histology and exclude a closely related one.
- A valid, recent biomarker report — PD-L1, MSI or TMB status where the protocol requires it, often from tissue of a specified age.
- Prior treatment lines — many studies require exactly none, or exactly one. Having had one cycle too many can close a door.
- Organ function on recent tests — blood counts, liver and kidney values must sit inside the protocol’s thresholds on the day.
- Performance status — most trials need you to be up and about for most of the day, which is why deferring the question until you are unwell often removes the option.
- Common exclusions — active autoimmune disease, a steroid dose above a stated limit, untreated brain metastases, active hepatitis B or C, or active tuberculosis.
- Practical ability to attend — the protocol’s visit calendar is compulsory, and it is set at the trial site, not at the centre nearest you.
A trial is a clinical decision that has a cost consequence — not a cost decision that has a clinical consequence. If a study is the right treatment for your disease, the fact that the drug is supplied is a welcome side effect of a sound decision. If it is not the right treatment, no amount of money saved makes it right. Ask your oncologist the clinical question first and the money question second, in that order.
CION does not provide CAR-T or other cell therapies. Where a CAR-T or cell-therapy study is what is being discussed, that is a referral to a centre that runs it, and this page is orientation only. This page is also information, not recruitment: nothing here is an offer of a place on any study, and no benefit is claimed for any investigational treatment.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Find Out What This Would Actually Cost You
A free consultation includes an indicative, itemised cost plan and an honest walk-through of every access route, including the ones that do not depend on a trial slot.
Finding one
How Do You Find an Immunotherapy Clinical Trial in India?
Ask your treating oncologist first, then check the official registers yourself. CTRI, the Clinical Trials Registry – India run by ICMR’s National Institute of Medical Statistics, is the register every Indian trial must be listed in. ClinicalTrials.gov carries global studies with Indian sites. Search by cancer type and city.
-
Ask the question at the consultation, out loud
Say that cost is the constraint and ask whether a trial is clinically reasonable for your diagnosis. It is a legitimate clinical input, not an embarrassment, and it changes what your oncologist puts in front of you.
-
Search the official register
Look your cancer type up on CTRI and on ClinicalTrials.gov, filtered to India. Note the registration number, the phase, the sponsor and the site city for anything that looks close.
-
Read the eligibility criteria against your own reports
Put the histopathology report, biomarker reports, recent bloods and a written list of every treatment already given side by side with the criteria. Most mismatches are visible before anyone makes a phone call.
-
Contact the site study team, not the sponsor
A register entry does not say whether recruitment is still open. Only the study coordinator at that site knows, and only they can tell you what screening involves and when a slot might exist.
-
Go into screening with your eyes open
Screening tests are usually paid by the study, but screening can end with a “no”. Keep the standard treatment plan alive in parallel so that a failed screening does not cost you weeks.
-
Read the consent document for the money, not only the medicine
Informed consent must be in a language you understand and you may take it home. The cost split, the travel position and the post-study position are all in there, and they are what decide whether this route works for your family.
| Ask the study team this | Why it decides your budget |
|---|---|
| Which items does the sponsor pay for, and which stay with us? | This single answer decides whether the trial is genuinely cheaper for you. Ask for it itemised and in writing. |
| Is there any reimbursement for travel or stay? | Some studies reimburse protocol visits and many do not. On a distant site this is often the biggest line you are left holding. |
| How many visits does the protocol add, and where? | Extra visits at a site far from home can cost a family more than the drug the study is supplying. |
| What happens if I come off the study, or it closes? | Post-trial supply is not automatic. Ask what treatment you move to and who pays for it from that day. |
| Who pays if a side effect needs treatment? | Medical management of a trial-related injury is the sponsor’s obligation under the 2019 rules. Unrelated illness is not. |
| What is the CTRI registration number, and is the ethics committee registered? | A number you can look up yourself is the simplest authenticity check available to a family. |
Timelines and terms described here are indicative, as of August 2026. Screening commonly takes one to three weeks from a complete set of reports, but no study is obliged to hold a slot for you while it runs.
The honest limits
Why a Trial Is Not a Financial Plan
Because you cannot schedule it. A suitable study may not be recruiting in the month you need treatment, the site may be in another state, the criteria may exclude you, randomisation may place you on the standard arm, and the study can close. Treat it as a possibility, and keep a funded plan behind it.
- Timing — cancer treatment has a clock. A trial that opens three months from now is not an option for a disease that needs a decision this week.
- Geography — sites cluster in a handful of cities. A protocol calendar you cannot physically keep is a plan that fails in month two.
- Narrow criteria — the protocol is written for a research question, not for the population of patients who need help paying.
- Randomisation — you may be assigned the current standard treatment instead of the investigational one, which changes your cost position entirely.
- The study can end — sponsors close studies, and arms are stopped. Continued supply afterwards depends on the protocol and is not automatic.
- It is not a benefit claim — an investigational treatment is being studied precisely because its place is not yet settled. No outcome is being promised to you here.
Run the funded plan in parallel, always. While a trial question is open, keep working on the routes that do not depend on a slot: government schemes and relief funds, charitable trusts and NGO support are set out in CM Relief Fund, PM Fund and NGO Support for Immunotherapy. Families who plan both at once lose nothing if the trial does not come through.
And decide what you are buying before you buy it. If the trial route closes, the question is no longer “can we find it cheaper” but “is this the right use of what we have” — a different decision, worked through in Is Immunotherapy Worth the Money? A Framework for Deciding. If money runs out after treatment has started, do not simply stop attending: What Happens If You Run Out of Money Mid-Treatment? sets out what to tell the treating team and when.
Before you plan around it
Money Should Not Be the Reason a Question Goes Unasked
Tell us where the cost is blocking you. We will be straight about what a trial can and cannot change, and about what the standard route would still cost.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
The Clinical Trial Route: Your Questions Answered
Is immunotherapy free if you join a clinical trial in India?
Often the drug is; the whole treatment rarely is. In most cancer drug trials the sponsor supplies the investigational immunotherapy at no charge and pays for the extra tests and scans the protocol adds. Standard care you would have needed anyway usually stays on your bill — day-care administration, routine pre-cycle bloods, supportive medicines, and all of your travel, stay and lost income. Under the New Drugs and Clinical Trials Rules, 2019, the sponsor must also provide free medical management for an injury related to the trial. Nothing is covered by default. Ask the study team to list, in writing, which items the sponsor pays for and which remain yours. Indicative, as of August 2026.
What does a clinical trial cover, and what do you still have to pay for?
The split follows the protocol, not fairness. Sponsors typically cover the investigational drug, any comparator drug the study supplies, the protocol-only bloods and imaging, the screening tests, and study-specific biomarker testing. Families typically still cover day-care chair time and nursing, routine monitoring that is standard care anyway, treatment of an illness unrelated to the trial, hospital admission for a reason outside the protocol, and every rupee of travel, accommodation, attendant time and lost work. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION and is billed by them unless the protocol pays for that specific scan. Reimbursement for travel exists in some studies and not in others. All of this is indicative, as of August 2026.
How do you find an immunotherapy clinical trial in India?
Start with your treating oncologist, then check the registers yourself. The Clinical Trials Registry – India (CTRI), run by ICMR's National Institute of Medical Statistics, is the official register and prospective registration is mandatory before the first participant is enrolled. ClinicalTrials.gov lists global studies that often include Indian sites. Search by cancer type and by city. A listing tells you a study exists; it does not tell you whether the site is still recruiting or whether you fit, and only the site study team can answer that. Have your histopathology report, biomarker reports, imaging and a written list of every treatment you have already had ready before you call. Guideline bodies including NCCN, ASCO and ESMO encourage considering a trial where one is clinically appropriate.
If you join a trial, will you definitely receive the immunotherapy drug?
No, and this is the part families most often miss. Many trials are randomised, which means a computer, not your doctor, assigns you to an arm. You may receive the current standard treatment rather than the investigational one, and some studies are blinded so neither you nor your treating team knows which you are on. In advanced cancer a placebo is generally added to standard treatment rather than given in place of it, but the design differs by study and the consent document is where you check. Enrolment itself is never assured either — screening tests can rule you out after the process has started. Plan your treatment on the assumption that the trial may not happen.
Is a clinical trial safe, and can you leave once you have joined?
Trials of a new drug in India need permission from CDSCO and clearance from a registered ethics committee, and you must give written informed consent in a language you understand. Monitoring on a trial is usually tighter than routine care, with more frequent bloods and reviews. The risks are real and, in early-phase studies, not fully known — that is why the study exists. You may withdraw at any time, for any reason, without losing your right to standard treatment at that centre. Before you consent, ask what treatment you would move to if you withdraw, if the study closes, or if the disease progresses, and ask who pays for it. Post-trial supply of the investigational drug is not automatic.
Does CION enrol patients into immunotherapy clinical trials?
This page is information, not recruitment, and nothing on it is an offer of a place on a study. CION Cancer Clinics administers approved immunotherapy as day care at its centres and coordinates response-assessment PET-CT at partner imaging centres. CION does not provide CAR-T or other cell therapies; where a cell-therapy study is being discussed, that is a referral to a centre that runs it. What a consultation can do is review whether a trial is a clinically sensible option for your diagnosis and your reports, tell you what documents a study team will ask for, and set out an indicative, itemised cost for the standard route alongside it so that you are comparing real numbers rather than hopes.